Search Result

Results for "

monoamine+oxidase+B

" in MedChemExpress (MCE) Product Catalog:

By Targets:	Monoamine Oxidase (61) Adenosine Receptor (1) Amyloid-β (3) Apoptosis (1) Biochemical Assay Reagents (1) Carbonic Anhydrase (1) Cholinesterase (ChE) (5) Cytochrome P450 (2) Dopamine Transporter (2) Drug Derivative (1) Endogenous Metabolite (1) Ferroptosis (1) Glutathione Peroxidase (1) Histamine Receptor (1) IKK (2) Imidazoline Receptor (1) Interleukin Related (2) Isotope-Labeled Compounds (2) JAK (2) Keap1-Nrf2 (1) Mitochondrial Metabolism (1) NO Synthase (2) Parasite (1) Reactive Oxygen Species (ROS) (4) Reference Standards (2) SOD (1) STAT (2) TNF Receptor (1) α-synuclein (1)
By Research Areas:	Cancer (1) Cardiovascular Disease (2) Inflammation/Immunology (5) Metabolic Disease (1) Neurological Disease (59)
Click Chemistry:	Alkynes (3)

Inhibitors & Agonists

Biochemical Assay Reagents

Natural
Products

Recombinant Proteins

Isotope-Labeled Compounds

Antibodies

Click Chemistry

Targets Recommended: Monoamine Oxidase

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-70057

Safinamide 2 Publications Verification FCE 26743; EMD 1195686	Monoamine Oxidase	Neurological Disease
Safinamide is a potent, selective, and reversible monoamine oxidase B (MAO-B) inhibitor (IC₅₀=0.098 μM) over MAO-A (IC₅₀=580 μM) . Safinamide also blocks sodium channels and modulates glutamate (Glu) release, showing a greater affinity at depolarized (IC₅₀=8 μM) than at resting (IC₅₀=262 μM) potentials. Safinamide has neuroprotective and neurorescuing effects and can be used for the study of parkinson disease, ischemia stroke etc.al .

HY-103164

(E)-8-(3-Chlorostyryl)caffeine (E)-CSC	Adenosine Receptor Monoamine Oxidase	Neurological Disease
(E)-8-(3-Chlorostyryl)caffeine is a selective adenosine A_2A receptor antagonist. (E)-8-(3-Chlorostyryl)caffeine inhibits monoamine oxidase B (MAO-B) with a K_i value of 70 nM by a pathway that is independent of its actions on the A_2A receptor. (E)-8-(3-Chlorostyryl)caffeine has the potential for Parkinson's disease research .

HY-13779

(E/Z)-J147	Monoamine Oxidase Dopamine Transporter	Neurological Disease
(E/Z)-J147 is an exceptionally potent, orally active, neuroprotective agent for cognitive enhancement. (E/Z)-J147 can readily pass the blood brain barrier (BBB). (E/Z)-J147 can inhibit monoamine oxidase B (MAO B) and the dopamine transporter with EC₅₀ values of 1.88 μM and 0.649 μM, respectively. (E/Z)-J147 has potential for the study of Alzheimer’s disease (AD) .

HY-70057A

Safinamide mesylate 2 Publications Verification FCE 26743 mesylate; EMD 1195686 mesylate	Monoamine Oxidase	Cardiovascular Disease Neurological Disease
Safinamide (FCE 26743; EMD 1195686) mesylate is a potent, selective, and reversible monoamine oxidase B (MAO-B) inhibitor (IC₅₀=0.098 μM) over MAO-A (IC₅₀=580 nM) . Safinamide mesylate also blocks sodium channels and modulates glutamate (Glu) release, showing a greater affinity at depolarized (IC₅₀=8?μM) than at resting (IC₅₀=262?μM) potentials. Safinamide mesylate has neuroprotective and neurorescuing effects and can be used for the study of parkinson disease, ischemia stroke et.al .

HY-76253

Benzylamine hydrochloride Phenylmethylamine	Biochemical Assay Reagents	Others
Benzylamine hydrochloride is a substrate for benzylamine oxidase and monoamine oxidase B.

HY-N0918

Desmethoxyyangonin Demethoxyyangonin; 5,6-Dehydrokavain	Monoamine Oxidase JAK IKK STAT NO Synthase Cytochrome P450	Neurological Disease Inflammation/Immunology
Desmethoxyyangonin is one of the six major kavalactones found in the Piper methysticum (kava) plant. Desmethoxyyangonin is a selective inhibitor of monoamine oxidase-B (MAO-B) (IC₅₀: 0.123 µM). Desmethoxyyangonin exerts anti-inflammatory effects by inhibiting Jak2/STAT3 and IKK signaling pathways. Desmethoxyyangonin induces CYP3A23 expression and leads to skeletal muscle relaxation .

HY-14201

Lazabemide Ro 19-6327	Monoamine Oxidase	Neurological Disease
Lazabemide (Ro 19-6327) is a selective, reversible inhibitor of monoamine oxidase B (MAO-B) (IC₅₀=0.03 μM) but less active for MAO-A (IC₅₀>100 μM). Lazabemide ?inhibits monoamine uptake at high concentrations, the IC₅₀ values are 86 μM, 123 μM and >500 μM for noradrenalin, serotonin and dopamine uptake, respectively. Lazabemide can be used for the research of parkinson and?alzheimer′s disease .

HY-13779A

J147	Monoamine Oxidase Dopamine Transporter	Neurological Disease
J147 is an exceptionally potent, orally active, neuroprotective agent for cognitive enhancement. J147 can pass the blood brain barrier (BBB). J147 can inhibit *monoamine oxidase B* (MAO B) and the dopamine transporter. J147 plays an impotant role in Alzheimer’s disease (AD) .

HY-114520

TT01001	Monoamine Oxidase Mitochondrial Metabolism Apoptosis Reactive Oxygen Species (ROS)	Neurological Disease Metabolic Disease
TT01001 is a selective and orally active mitoNEET agonist and a monoamine oxidase B (MAO-B) inhibitor (IC₅₀ = 8.84 μM). TT01001 does not activate PPARγ but interacts with MitoNEET. TT01001 attenuates oxidative stress and neuronal apoptosis by preventing mitoNEET-mediated mitochondrial dysfunction. TT01001 improves type II diabetes and ameliorates mitochondrial function of mice. TT01001 can used for the studies of type II diabetes and neurological disorders .

HY-N9540

Methyl citrate	Monoamine Oxidase	Neurological Disease
Methyl citrate is a Monoamine oxidase B (MAO-B) inhibitor (IC₅₀=0.23 mM). Methyl citrate is isolated from the fruits of Opuntia ficus-indica var. saboten Makino .

HY-N4037

Homopterocarpin (-)-Homopterocarpin; 3,9-Dimethoxypterocarpan	Monoamine Oxidase Parasite	Inflammation/Immunology
Homopterocarpin is an isoflavonoid that can be isolated from Pterocarpus erinaceus. Homopterocarpin has hepatoprotective, antioxidant and antiplasmodial activity. Homopterocarpin is a competitive reversible inhibitor of human monoamine oxidase-B with an IC₅₀ and a K_i of 0.72 and 0.21 μM for hMAO-B, respectively. Homopterocarpin can be used for the research of liver injury and oxidative stress .

HY-120419

PF9601N	Monoamine Oxidase	Neurological Disease
PF9601N, an *monoamine oxidase B* (MAO-B) inhibitor, possesses neuroprotective properties in several in vitro and in vivo models of Parkinson's disease (PD). PF9601N can be used for the research of neurodegenerative diseases mediated by excitotoxicity . PF9601N is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.

HY-W083062

hMAO-B-IN-5	Monoamine Oxidase	Neurological Disease
hMAO-B-IN-5 (Compound B15) is a potent, selective and reversible *human monoamine oxidase-B* (hMAO-B) inhibitor with an IC₅₀ of 120 nM and a K_i** of 33 nM. hMAO-B-IN-5 can be used in the research of neurodegenerative diseases .

HY-14202

Lazabemide hydrochloride Ro 19-6327 hydrochloride	Monoamine Oxidase	Neurological Disease
Lazabemide hydrochloride (Ro 19-6327 hydrochloride) is a selective, reversible inhibitor of monoamine oxidase B (MAO-B) (IC₅₀=0.03 μM) but less active for MAO-A (IC₅₀>100 μM). Lazabemide inhibits monoamine uptake at high concentrations, the IC₅₀ values are 86 μM, 123 μM and >500 μM for noradrenalin, serotonin and dopamine uptake, respectively. Lazabemide can be used for the research of parkinson and alzheimer′s disease .

HY-152671

hMAO-B-IN-4	Monoamine Oxidase	Neurological Disease
hMAO-B-IN-4 (compound B10) is a selective, reversible and blood–brain barrier (BBB) penetrable human monoamine oxidase-B (hMAO-B) inhibitor with an IC₅₀ value and a K_i value of 0.067 and 0.03 μM, respectively. hMAO-B-IN-4 inhibits hMAO-A with an IC₅₀ value of 33.82 μM. hMAO-B-IN-4 can be used for Alzheimer’s disease (AD) and Parkinson’s disease (PD) research .

HY-W628136

MAO-B-IN-47	Monoamine Oxidase	Neurological Disease
MAO-B-IN-47 is a selective *monoamine oxidase B* (MAO-B) inhibitor with a K_i of 875 nM. MAO-B-IN-47 shows an IC₅₀ >100 μM for SH-SY5Y cells. MAO-B-IN-47 shows neuroprotective effect in 6-OHDA-treated SH-SY5Y cells. MAO-B-IN-47 can be used for the research of neurological disease, such as Parkinson’s disease (PD) .

HY-70057S1

Safinamide-d4-1 FCE 26743-d₄-1; EMD 1195686-d₄-1	Isotope-Labeled Compounds Monoamine Oxidase	Neurological Disease
Safinamide-d₄-1 is deuterium labeled Safinamide. Safinamide is a potent, selective, and reversible monoamine oxidase B (MAO-B) inhibitor (IC₅₀=0.098 μM) over MAO-A (IC₅₀=580 μM) . Safinamide also blocks sodium channels and modulates glutamate (Glu) release, showing a greater affinity at depolarized (IC₅₀=8?μM) than at resting (IC₅₀=262?μM) potentials. Safinamide has neuroprotective and neurorescuing effects and can be used for the study of parkinson disease, ischemia stroke etc.al .

HY-151562

AChE/BuChE/MAO-B-IN-1	Cholinesterase (ChE) Monoamine Oxidase	Neurological Disease
AChE/BuChE/MAO-B-IN-1 (compound 19) is an inhibitor of human acetyl- (hAChE), butyrylcholinesterase (hBuChE) and monoamine oxidase-B (hMAO-B) with IC₅₀s of 4.8 μM, 13.7 μM, and 1.11 μM, respectively. AChE/BuChE/MAO-B-IN-1 also exhibits high affinity to both the σ₁ and σ₂ receptors with K_i values of 42.8 nM (human σ₁ receptor) and 191 nM (rat σ₂ receptor), respectively. AChE/BuChE/MAO-B-IN-1 can be used for Alzheimer’s disease research .

HY-162573

Monoamine Oxidase B inhibitor 5	Monoamine Oxidase	Neurological Disease
Monoamine Oxidase B inhibitor 5 (Compound 16d) is a selective and reversible inhibitor for monoamine oxidase B (hMAO-B) with an IC₅₀ of 67.3 nM and a K_i of 82.5 nM. Monoamine Oxidase B inhibitor 5 exhibits good pharmacokinetic characters and weak toxicity in rats model. Monoamine Oxidase B inhibitor 5 alleviates MPTP-induced (HY-15608) motor impairment in Parkinson’s mouse model. Monoamine Oxidase B inhibitor 5 is blood-brain barrier (BBB) penetrate .

HY-143245

Monoamine Oxidase B inhibitor 2	Monoamine Oxidase	Neurological Disease
Monoamine Oxidase B inhibitor 2 is a potent, reversible, orally active and selective monoamine oxidase B (MAO-B) inhibitor with an IC₅₀ of 1.33 nM. Monoamine Oxidase B inhibitor 2 has antioxidant and anti-neuroinflammatory activities. Monoamine Oxidase B inhibitor 2 can across the blood-brain barrier (BBB), and can be used for Parkinson’s disease study .

HY-143244

Monoamine Oxidase B inhibitor 1	Monoamine Oxidase	Neurological Disease
Monoamine Oxidase B inhibitor 1 is a potent, reversible, orally active and selective monoamine oxidase B (MAO-B) inhibitor with an IC₅₀ of 0.02 nM. Monoamine Oxidase B inhibitor 1 has antioxidant and anti-neuroinflammatory activities. Monoamine Oxidase B inhibitor 1 can across the blood-brain barrier (BBB), and can be used for Parkinson’s disease study .

HY-161674

Monoamine Oxidase B inhibitor 4	Monoamine Oxidase	Neurological Disease
Monoamine Oxidase B inhibitor 4 (compound 1l) is a selective inhibitor of human monoamine oxidase-B (hMAO-B) (IC50=8.3 nM). Monoamine Oxidase B inhibitor 4 also has anti-neuroinflammatory and low neurotoxicity. Monoamine Oxidase B inhibitor 4 can inhibit the release of NO, TNF-α and IL-1β stimulated by LPS and Aβ1-42, and can also attenuate Aβ(1-42)-induced cytotoxicity .

HY-170798

Monoamine Oxidase B inhibitor 6	Monoamine Oxidase SOD Glutathione Peroxidase	Neurological Disease
Monoamine Oxidase B inhibitor 6 (Compound BT5) is a BBB-penetrable, highly selective, reversible and competitive MAO-B inhibitor, with an IC₅₀ of 0.11 μM. Monoamine Oxidase B inhibitor 6 has antioxidant and neuroprotective effects and can be used in the research of neurodegenerative diseases .

HY-U00015

MAO-IN-1	Monoamine Oxidase	Neurological Disease
MAO-IN-1 is a monoamine oxidase B (MAO B) inhibitor with an IC₅₀ of 20 nM.

HY-U00343

MAO-B-IN-1	Monoamine Oxidase	Neurological Disease
MAO-B-IN-1 is an inhibitor of *monoamine oxidase B*, used for the research of neurological diseases.

HY-147362

MAO-B-IN-14	Monoamine Oxidase	Neurological Disease
MAO-B-IN-14 (Compound 9) is a potent and selective monoamine oxidase-B (MAO-B) inhibitor with an IC₅₀ of 0.95 μM and a K_i of 0.55 μM against human MAO-B.

HY-70057R

Safinamide (Standard) FCE 26743 (Standard); EMD 1195686 (Standard)	Reference Standards Monoamine Oxidase	Neurological Disease
Safinamide (Standard) is the analytical standard of Safinamide. This product is intended for research and analytical applications. Safinamide is a potent, selective, and reversible monoamine oxidase B (MAO-B) inhibitor (IC₅₀=0.098 µM) over MAO-A (IC₅₀=580 µM) . Safinamide also blocks sodium channels and modulates glutamate (Glu) release, showing a greater affinity at depolarized (IC₅₀=8 µM) than at resting (IC₅₀=262 µM) potentials. Safinamide has neuroprotective and neurorescuing effects and can be used for the study of parkinson disease, ischemia stroke etc.al .

HY-161328

MAO-B-IN-31	α-synuclein	Neurological Disease
MAO-B-IN-31 (Compound 30) is an effective and selective inhibitor of monoamine oxidase B (monoamine oxidase B). The IC₅₀ value is 41 nM. MAO-B-IN-31 also inhibits α-syn and tau aggregation. MAO-B-IN-31 has neuroprotective activity .

HY-114915

PSB-1434	Monoamine Oxidase	Neurological Disease
PSB-1434 is a selective monoamine oxidase B (MAO-B) inhibitor with an IC₅₀ of 1.59 nM. PSB-1434 shows >6000-fold selective for MAO-B than MAO-A .

HY-146149

MAO-B-IN-11	Monoamine Oxidase	Neurological Disease
MAO-B-IN-11 (Compound 8c) is a potent monoamine oxidase B (MAO-B) inhibitor with an IC₅₀ of 1.3 μM. MAO-B-IN-11 shows a neuroprotective activity .

HY-146150

MAO-B-IN-12	Monoamine Oxidase	Neurological Disease
MAO-B-IN-12 (Compound 16c) is a potent monoamine oxidase B (MAO-B) inhibitor with an IC₅₀ of 1.3 μM. MAO-B-IN-12 shows a neuroprotective activity .

HY-151210

MAO-B-IN-17	Monoamine Oxidase	Neurological Disease
MAO-B-IN-17 is a selective *monoamine oxidase B* (MAO-B) inhibitor with the IC₅₀ value of 5.08 μM. MAO-B-IN-17 can be used in Parkinson’s disease research .

HY-116097

PSB-1491	Monoamine Oxidase	Neurological Disease
PSB-1491 is a selective and competitive monoamine oxidase B (MAO-B) inhibitor with an IC₅₀ of 0.386 nM for hMAO-B. PSB-1491 shows >25000-fold selective versus MAO-A .

HY-151208

MAO-B-IN-16	Monoamine Oxidase	Neurological Disease
MAO-B-IN-16 is a selective *monoamine oxidase B* (MAO-B) inhibitor, with an IC₅₀ of 1.55 µM. MAO-B-IN-16 can be used in the study of central nervous disorders, such as parkinson's disease .

HY-123665

PSB-1410	Monoamine Oxidase	Neurological Disease
PSB-1410 is a monoamine oxidase B (MAO-B) inhibitor, with an IC₅₀ of 0.227 nM against human MAO-B and an IC₅₀ of 1.01 nM against rat MAO-B. PSB-1410 can be used for the research of Parkinson's disease .

HY-162303

C175-0062	Monoamine Oxidase	Neurological Disease
C175-0062 is a monoamine oxidase B (MAO-B) inhibitor. C175-0062 can be used for the research of neurodegenerative disorders, including Parkinson's disease (PD), Alzheimer’s disease (AD), and amyotrophic lateral sclerosis (ALS) .

HY-117502

SL-25.1188	Monoamine Oxidase	Others
SL-25.1188 is a potent monoamine oxidase B (MAO-B) inhibitor with K_i values of 2.9 and 8.5 nM for human MAO-B and rat MAO-B, respectively. SL-25.1188 can be used for positron emission tomography .

HY-168728

MAO-B-IN-37	Monoamine Oxidase	Neurological Disease
MAO-B-IN-37 (Compound 37) is a derivative of TT01001 (HY-114520), and a selective inhibitor for monoamine oxidase B (MAO-B) with an IC₅₀ of 270 nM. MAO-B-IN-37 exhibits good metabolic stability in mice microsomes and good affinity with human serum albumin .

HY-160002

MAO-B-IN-27	Monoamine Oxidase	Neurological Disease
MAO-B-IN-27 (Compound 12c) is a monoamine oxidase B (MAO-B) inhibitor. MAO-B-IN-27 has potent and selective MAO-B inhibitory effect for hMAO-B with an IC₅₀ values of 8.9 nM. MAO-B-IN-27 can be used for the research of parkinson's disease (PD) .

HY-163380

CA/MAO-B-IN-1	Carbonic Anhydrase	Neurological Disease
CA/MAO-B-IN-1 (Compound 78) is a dual inhibitor for human brain carbonic anhydrases (CA) and Monoamine Oxidase-B (MAO-B), with IC₅₀s of 8.8 and 7.0 nM, respectively. CA/MAO-B-IN-1 reveals a human oral absorption of 71.9% through in silico prediction .

HY-157400

hMAO-B-IN-7	Monoamine Oxidase	Neurological Disease
hMAO-B-IN-7 (compound 11n) is a potent and blood–brain barrier (BBB) penetrable inhibitor of human monoamine oxidase-B (hMAO-B), with the IC₅₀ value of 0.79±0.05 μM. hMAO-B-IN-7 can be used for Alzheimer’s disease (AD) and Parkinson’s disease (PD) research .

HY-178139

hMAO-B-IN-12	Monoamine Oxidase	Cardiovascular Disease
hMAO-B-IN-12 (Compound 6E) is a highly selective human monoamine oxidase B (hMAO-B) inhibitor (IC₅₀=17.7 nM). hMAO-B-IN-12 reduces oxidative stress/lipid metabolism-derived products (e.g., H₂O₂). hMAO-B-IN-12 is promising for research of atherosclerosis .

HY-146347

MAO-B-IN-10	Monoamine Oxidase Amyloid-β	Neurological Disease
MAO-B-IN-10 (compound 4f) is a potent, selective, BBB-penetrated MAO-B (monoamine oxidase-B) inhibitor, with IC₅₀ of 5.3 μM. MAO-B-IN-10 can inhibit (58.2%) and disaggregate (43.3%) self-mediated Aβ (amyloid β) aggregation. MAO-B-IN-10 can be use for Alzheimer’s disease research .

HY-101301A

RS 45041-190 hydrochloride	Imidazoline Receptor	Neurological Disease
RS 45041-190 hydrochloride is a high-affinity ligand for I2 imidazoline receptors, with the pK_is of 8.66, 9.37, 9.32, and 8.85 in rat, rabbit, dog and baboon kidney, respectively. RS 45041-190 hydrochloride shows moderate potency for the inhibition of monoamine oxidase A in vitro (pIC₅₀= 6.12), but had much lower potency for *monoamine oxidase B* (pIC₅₀ = 4.47) .

HY-N13041

Acacetin 7-O-(6-O-malonylglucoside)	Monoamine Oxidase	Neurological Disease
Acacetin 7-O-(6-O-malonylglucoside) is a *monoamine oxidase* inhibitor with strong inhibitory effects on monoamine oxidase A (MAO-A) and monoamine oxidase B (MAO-B) with IC₅₀ values of 2.34 and 1.87 μM, respectively. Acacetin 7-O-(6-O-malonylglucoside) is a reversible MAO inhibitor that can be used in the research of neurodegenerative diseases and affective disorders .

HY-173138

FCOB02	Monoamine Oxidase	Neurological Disease
FCOB02 is a monoamine oxidase B (MAO-B) ligand. FCOB02 can be labeled as [18F]FCOB02, a 4-methylcoumarin-like targeting probe. [18F]FCOB02 has a high affinity for MAO-B with an IC₅₀ of 10.68 nM. [18F]FCOB02 can be used in specific MAO-B imaging as well as quantitative analysis in vivo .

HY-N0918R

Desmethoxyyangonin (Standard) Demethoxyyangonin (Standard); 5,6-Dehydrokavain (Standard)	Reference Standards Monoamine Oxidase JAK STAT NO Synthase IKK Cytochrome P450	Neurological Disease Inflammation/Immunology
Desmethoxyyangonin (Standard) is one of the six major kavalactones found in the Piper methysticum (kava) plant. Desmethoxyyangonin (Standard) is a selective inhibitor of monoamine oxidase-B (MAO-B) (IC₅₀: 0.123 µM). Desmethoxyyangonin (Standard) exerts anti-inflammatory effects by inhibiting Jak2/STAT3 and IKK signaling pathways. Desmethoxyyangonin (Standard) induces CYP3A23 expression and leads to skeletal muscle relaxation .

HY-W269511

NW-1689	Drug Derivative	Neurological Disease
NW-1689 is a process-related impurity of safinamide mesilate (SAFM). SAFM can be used for the study of Parkinson's disease (PD). It is a highly selective and reversible inhibitor of monoamine oxidase-B (MAO-B) and also blocks sodium channels and N-type calcium channels. These effects of SAFM help reduce the breakdown of dopamine and inhibit the release of glutamate. NW-1689 has a similar chemical structure to SAFM and has some similar pharmacological effects as SAFM, and can be used in Parkinson's disease research .

HY-146383

H3R antagonist 2	Histamine Receptor Cholinesterase (ChE) Monoamine Oxidase	Neurological Disease
H3R antagonist 2 (Compound 23) is a multitarget histamine H₃ receptor (H₃R) antagonist with a K_i of 170 nM for hH₃R . H3R antagonist 2 shows inhibitory effects with IC₅₀ values of 180, 880 and 775 nM for acetylcholinesterase, butyrylcholinesterase and *human monoamine oxidase B* (hMAO B)**, respectively. H3R antagonist 2 shows favorable anti-neuropathic pain and memory-enhancing effects. H3R can across BBB .

HY-173334

hMAO-B-IN-11	Monoamine Oxidase Interleukin Related TNF Receptor	Neurological Disease
hMAO-B-IN-11 (Compound 12) is a selective and reversible inhibitor of human monoamine oxidase B (hMAO-B) with an IC₅₀ of 0.11 µM. hMAO-B-IN-11 acts through competitive binding to the hMAO-B active site, preventing oxidative deamination of monoamines and reducing hydrogen peroxide production. hMAO-B-IN-11 also inhibits pro-inflammatory mediators (NO, TNF-α, IL-1β) in activated microglia, hMAO-B-IN-11 is promising for research of neurodegenerative diseases like Parkinson’s and Alzheimer’s .

Cat. No.	Product Name	Category	Target	Chemical Structure

HY-N0918

Desmethoxyyangonin Demethoxyyangonin; 5,6-Dehydrokavain	other families Classification of Application Fields Other Diseases Other Phenylpropanoids Phenylpropanoids Plants Disease Research Fields Source Classification	Monoamine Oxidase JAK IKK STAT NO Synthase Cytochrome P450
Desmethoxyyangonin is one of the six major kavalactones found in the Piper methysticum (kava) plant. Desmethoxyyangonin is a selective inhibitor of monoamine oxidase-B (MAO-B) (IC₅₀: 0.123 µM). Desmethoxyyangonin exerts anti-inflammatory effects by inhibiting Jak2/STAT3 and IKK signaling pathways. Desmethoxyyangonin induces CYP3A23 expression and leads to skeletal muscle relaxation .

HY-N9540

Methyl citrate	Cactaceae Ketones, Aldehydes, Acids Opuntia ficus-indica (L.) Mill. Plants Source Classification	Monoamine Oxidase
Methyl citrate is a Monoamine oxidase B (MAO-B) inhibitor (IC₅₀=0.23 mM). Methyl citrate is isolated from the fruits of Opuntia ficus-indica var. saboten Makino .

HY-N4037

Homopterocarpin (-)-Homopterocarpin; 3,9-Dimethoxypterocarpan	Other Terpenoids Pterocarpus indicus willd. Structural Classification Leguminosae Terpenoids Plants Source Classification	Monoamine Oxidase Parasite
Homopterocarpin is an isoflavonoid that can be isolated from Pterocarpus erinaceus. Homopterocarpin has hepatoprotective, antioxidant and antiplasmodial activity. Homopterocarpin is a competitive reversible inhibitor of human monoamine oxidase-B with an IC₅₀ and a K_i of 0.72 and 0.21 μM for hMAO-B, respectively. Homopterocarpin can be used for the research of liver injury and oxidative stress .

HY-N13041

Acacetin 7-O-(6-O-malonylglucoside)	Flavonoids Flavones Ligularia veitchiana (Hemsl.) Greenm. Labiatae Plants Source Classification	Monoamine Oxidase
Acacetin 7-O-(6-O-malonylglucoside) is a *monoamine oxidase* inhibitor with strong inhibitory effects on monoamine oxidase A (MAO-A) and monoamine oxidase B (MAO-B) with IC₅₀ values of 2.34 and 1.87 μM, respectively. Acacetin 7-O-(6-O-malonylglucoside) is a reversible MAO inhibitor that can be used in the research of neurodegenerative diseases and affective disorders .

HY-N0918R

Desmethoxyyangonin (Standard) Demethoxyyangonin (Standard); 5,6-Dehydrokavain (Standard)	Structural Classification other families Other Phenylpropanoids Phenylpropanoids Plants Source Classification	Reference Standards Monoamine Oxidase JAK STAT NO Synthase IKK Cytochrome P450
Desmethoxyyangonin (Standard) is one of the six major kavalactones found in the Piper methysticum (kava) plant. Desmethoxyyangonin (Standard) is a selective inhibitor of monoamine oxidase-B (MAO-B) (IC₅₀: 0.123 µM). Desmethoxyyangonin (Standard) exerts anti-inflammatory effects by inhibiting Jak2/STAT3 and IKK signaling pathways. Desmethoxyyangonin (Standard) induces CYP3A23 expression and leads to skeletal muscle relaxation .

HY-N3614

Confluentic acid	Natural Products Microorganisms Source Classification	Others
Confluentic acid exhibits selective inhibition of Monoamine oxidase B, demonstrating an IC50 value of 0.22 micromolar.

Cat. No.	Compare	Product Name	Species	Source	Image

HY-P704121

	MAOB Protein, Human (Active, sf9, His) MAOB, MAO-B,Monoamine Oxidase B,Monoamine oxidase type B	Human	Sf9 insect cells
	MAOB Protein, Human (Active, sf9, His) is the recombinant human-derived MAOB protein, expressed by Sf9 insect cells, with N-His tag. This product contains detergent and is not suitable for cell-related experiments.

Compare Products


Products	In-stock - + Add to Cart
Cat. No.
Species
Source
Tag
Accession
Gene ID
Molecular Weight
Purity
Endotoxin Level
Biological Activity
Appearance
Formulation
Storage & Stability
Shipping
Free Sample	Yes No
Size	* This product has been "discontinued". Optimized version of product available: / In-stock - + Add to Cart Get quote

Cat. No.	Product Name	Chemical Structure

HY-70057S1

Safinamide-d4-1

Safinamide-d₄-1 is deuterium labeled Safinamide. Safinamide is a potent, selective, and reversible monoamine oxidase B (MAO-B) inhibitor (IC₅₀=0.098 μM) over MAO-A (IC₅₀=580 μM) . Safinamide also blocks sodium channels and modulates glutamate (Glu) release, showing a greater affinity at depolarized (IC₅₀=8?μM) than at resting (IC₅₀=262?μM) potentials. Safinamide has neuroprotective and neurorescuing effects and can be used for the study of parkinson disease, ischemia stroke etc.al .

HY-70057S4

Safinamide-d5

Safinamide-d₅ (FCE 26743-d₅) is deuterium labeled Safinamide. Safinamide is a potent, selective, and reversible monoamine oxidase B (MAO-B) inhibitor (IC₅₀=0.098 μM) over MAO-A (IC₅₀=580 μM) . Safinamide also blocks sodium channels and modulates glutamate (Glu) release, showing a greater affinity at depolarized (IC₅₀=8?μM) than at resting (IC₅₀=262?μM) potentials. Safinamide has neuroprotective and neurorescuing effects and can be used for the study of parkinson disease, ischemia stroke etc.al .

Cat. No.	Compare	Product Name	Application	Reactivity	Image

HY-P82294

	Monoamine Oxidase B Antibody (YA2039) Adrenalin oxidase; MAO; brain; MAO; platelet; MAOB	WB, IHC-P	Human
	Monoamine Oxidase B Antibody (YA2039) is a Rabbit-derived and non-conjugated IgG monoclonal antibody, targeting to Monoamine Oxidase B.

Compare Products


Products	In-stock - + Add to Cart
Cat. No.
Host
Reactivity
Application
Dilution Ratio
Molecular Weight
Conjugation
Clonality
Immunogen
Appearance
Isotype
Gene ID
SwissProt ID
Purity
Formulation
Free Sample	Yes No
Size	* This product has been "discontinued". Optimized version of product available: / In-stock - + Add to Cart Get quote

Cat. No.	Product Name		Classification

HY-120419

PF9601N		Alkynes
PF9601N, an *monoamine oxidase B* (MAO-B) inhibitor, possesses neuroprotective properties in several in vitro and in vivo models of Parkinson's disease (PD). PF9601N can be used for the research of neurodegenerative diseases mediated by excitotoxicity . PF9601N is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.

HY-146314

MAO-B-IN-9		Alkynes
MAO-B-IN-9 (compound 16) is a potent, selective, BBB-penetrated, irreversible and time-dependent MAO-B (monoamine oxidase B) inhibitor, with an IC₅₀ of 0.18 μM. MAO-B-IN-9 prevents Aβ_1-42-induced neuronal cell death. MAO-B-IN-9 shows neuroprotective effects, which may be the result of its Aβ_1-42 anti-aggregation effects . MAO-B-IN-9 is a click chemistry reagent, itcontains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.

HY-181268

MAO-B-IN-53		Alkynes
MAO-B-IN-53 is a human monoamine oxidase B (hMAO-B) inhibitor with an IC₅₀ of 0.066 μM. MAO-B-IN-53 exhibits mixed reversible inhibition, binds stably to the hMAO-B active site, and shows high selectivity over hMAO-A. MAO-B-IN-53 acts as a neuroprotective agent, protects against 6-OHDA-induced damage, and exhibits low neurotoxicity in neuroblastoma cells. MAO-B-IN-53 can be used for the research of Parkinson's disease .

Inquiry Online

Your information is safe with us. * Required Fields.

MCE Japan Authorized Agent ナミキ商事株式会社コスモ・バイオ株式会社重松貿易株式会社
Salutation			Country or Region *
Applicant Name *			Organization Name *
Department *
Email Address *			Product Name *
Cat. No.			Requested quantity *
Phone Number *
Remarks